Saturday, May 18, 2024
HomeFunding MA-based Red Arrow Therapeutics Inc. Secures $4.5Million in Seed Extension Round...

[Funding alert] MA-based Red Arrow Therapeutics Inc. Secures $4.5Million in Seed Extension Round Funding

Red Arrow Therapeutics Inc., located in Massachusetts, has raised $4.5 million for a seed extension round. The following companies took part in this round: OSAKA University Venture Capital Co., Ltd., Keio Innovation Initiative, Inc., The University of Tokyo Edge Capital Partners Co., Ltd., and Beyond Next Ventures Inc.

Red Arrow Therapeutics Inc., located in Massachusetts, has raised $4.5 million for a seed extension round. The following companies took part in this round: OSAKA University Venture Capital Co., Ltd., Keio Innovation Initiative, Inc., The University of Tokyo Edge Capital Partners Co., Ltd., and Beyond Next Ventures Inc.

The company’s flagship drug, IL-12-loaded nanopolymeric micelles, will enable it to gather important preclinical data on safety and efficacy through the Seed extension round. Additionally, the investment will make it possible to start production in cooperation with outside partners.

Read also – CA-based Anvilogic Secures $45Million in Series C Round Funding

With this and prior financing from The University of Tokyo Edge Capital Partners Co., Ltd., University of California, Berkeley’s accelerator SkyDeck, and other non-dilutive funding, Red Arrow Therapeutics has raised a total of roughly $5.5 million.

Red Arrow Therapeutics, which was founded in 2021 by graduates of the University of Tokyo’s Cabral Lab, creates pH-sensing nanomedicine drug delivery systems for a variety of therapeutic applications, including cancer.

About Red Arrow Therapeutics, Inc.

Red Arrow Therapeutics, Inc. is a biotechnology business dedicated to creating novel technologies capable of converting “cold” tumours into “hot” tumours that are inflamed. The primary product candidate from Red Arrow Therapeutics, RA-001, is a pH-activated polymer micelle that is loaded with IL-12 and is intended to safely enhance immunotherapy by releasing fully active IL-12 upon sensing intratumoral pH.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular